Mink Therapeutics’ Earnings Call: High Promise, Tight Runway

Mink Therapeutics, Inc. ((INKT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Mink Therapeutics’ latest earnings call struck a cautiously optimistic tone as management highlighted promising clinical signals alongside familiar risks for an early‑stage biotech. Executives emphasized meaningful progress in oncology and acute lung injury, backed by strong translational science and efficient manufacturing, while acknowledging that limited cash and trial execution risk will make the next year pivotal for shareholders.

Robust translational and clinical presentations

Mink spotlighted data from four major scientific meetings, spanning pulmonary fibrosis, oncology and severe lung injury. Management argued that agent 797 shows coherent biology across cancer and ARDS, with the same donor‑derived iNKT cell product driving tumor‑killing TH1 responses in cancer but more restorative immune signaling in lung injury and fibrosis.

Remarkable survival signal in refractory gastric cancer

The company underscored a standout signal in heavily pretreated checkpoint‑refractory gastroesophageal cancer, where median overall survival has exceeded 23 months in the primary Phase II cohort. Several patients remain alive years after dosing, an outcome that compares favorably with historical expectations measured in just a few months for this population.

Randomized Phase II ARDS trial with seamless Phase II/III design

Management announced that a randomized Phase II trial in severe acute lung injury and ARDS is now underway with roughly 90 patients split 1:1 between agent 797 plus standard care and placebo plus standard care. The study is structured as a seamless Phase II/III program, already cleared for dosing by regulators in both Ukraine and the U.S., aiming to accelerate any path toward registration.

Clear early endpoints and near‑term data plan

The ARDS trial will track hard clinical outcomes including overall survival, ventilator‑free days and ICU days to quickly gauge whether the therapy meaningfully changes patient trajectories. Mink expects early data to support a go or no‑go decision and plans to share preliminary results in the second half of 2026, giving investors a defined catalyst horizon.

Manufacturing scale and off‑the‑shelf readiness

On the manufacturing front, Mink highlighted a scalable process that can generate billions of iNKT cells from a single donor, stored cryogenically and used without HLA matching or lymphodepletion. This off‑the‑shelf profile is designed for rapid deployment in real‑world ICU settings and the company says it already has material for most of its planned clinical work, limiting incremental manufacturing spend.

Partnerships and non‑dilutive support

The call detailed collaborations that bring non‑dilutive funding and strategic value, including a partnered program in pediatric cancers and combination efforts with ImmunityBio’s IL‑15 superagonist. An operational partnership in Ukraine is helping Mink run its ARDS program in a demanding critical care environment, potentially sharpening real‑world relevance while stretching limited capital.

Disciplined financial execution amid ongoing losses

Financially, Mink reported a Q1 2026 net loss of about $2.7 million, slightly better than the prior year’s $2.8 million, with loss per share improving to $0.57 from $0.70. Management framed this as evidence of disciplined cost control while still funding key trials, but also confirmed that the business remains in a loss‑making, cash‑consuming phase.

Limited cash and near‑term financing overhang

The balance sheet remains a central concern, with quarter‑end cash at roughly $9.5 million, down from $13.4 million at year‑end despite raising around $3 million in aftermarket equity and repaying $5.2 million of convertible notes. While management believes this provides at least 12 months of runway, investors will likely anticipate additional financing if the ARDS trial and oncology work both advance as planned.

Early‑stage data and ARDS development risks

Executives stressed that many positive signals come from investigator‑led early‑phase studies, translational work and case reports that are not yet registrational in nature. In ARDS specifically, they acknowledged the field’s checkered history with cell therapies, the biologic heterogeneity of the disease and the need to generate clear survival benefits where previous approaches have struggled.

Operational and regulatory uncertainties

Part of the ARDS program depends on Ukrainian and other international sites, which introduces elevated geopolitical and logistical risk even as Mink reports successful cell deliveries to date. The company is also still refining biomarker‑based stratification and continues its dialogue with the FDA, leaving room for shifts in trial design, regulatory expectations and timelines as those discussions progress.

Forward‑looking guidance and key upcoming catalysts

Looking ahead, management guided that the 90‑patient randomized Phase II ARDS study is now enrolling on a seamless Phase II/III track, with planned regulatory interactions in the coming weeks and preliminary data expected in the second half of 2026. They reiterated that roughly 100 patients have been treated across programs, highlighted the >23‑month median overall survival in refractory gastric cancer and emphasized that existing cell inventory and a reported 12‑month cash runway should support near‑term milestones.

Mink Therapeutics’ call painted a picture of a company with compelling early clinical signals and a scalable platform but operating under tight financial and execution constraints. For investors, the story now hinges on whether upcoming ARDS data and further validation of the gastric cancer signal can justify the capital and risk required to carry this high‑potential cell therapy story into later‑stage trials.